Drug Profile

Research programme: dual mechanism Na/K channel and SERCA2a activators - Windtree Therapeutics

Alternative Names: Chronic heart failure therapy - Windtree Therapeutics; CV-IST2

Latest Information Update: 07 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CVie Therapeutics
Developer Windtree Therapeutics
Class Heart failure therapies
Mechanism of Action Sarcoplasmic reticulum calcium-transporting ATPase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

01 Feb 2024 Windtree renews agreement with Chang Gung University for SERCA2a research
17 Jan 2024 SERCA2a activators licensed to Lee's Pharmaceuticals in Greater China
23 Aug 2023 USPTO issues patent for dual mechanism SERCA2a activators in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com